|
1
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ostrom QT, Gittleman H, Fulop J, Liu M,
Blanda R, Kromer C, Wolinsky Y, Kruchko C and Barnholtz-Sloan JS:
CBTRUS Statistical Report: Primary brain and central nervous system
tumors diagnosed in the United States in 2008-2012. Neuro-oncol.
17(Suppl 4): pp. iv1–iv62. 2015, View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van den Bent MJ and Bromberg JE:
Neuro-oncology: The many challenges of treating elderly
glioblastoma patients. Nat Rev Neurol. 11:374–375. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dirven L, Aaronson NK, Heimans JJ and
Taphoorn MJ: Health-related quality of life in high-grade glioma
patients. Chin J Cancer. 33:40–45. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mora A, Komander D, van Aalten DM and
Alessi DR: PDK1, the master regulator of AGC kinase signal
transduction. Semin Cell Dev Biol. 15:161–170. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pearce LR, Komander D and Alessi DR: The
nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol.
11:9–22. 2010. View
Article : Google Scholar
|
|
7
|
Raimondi C and Falasca M: Targeting PDK1
in cancer. Curr Med Chem. 18:2763–2769. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garcia-Echeverria C and Sellers WR: Drug
discovery approaches targeting the PI3K/Akt pathway in cancer.
Oncogene. 27:5511–5526. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pinner S and Sahai E: PDK1 regulates
cancer cell motility by antagonising inhibition of ROCK1 by RhoE.
Nat Cell Biol. 10:127–137. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
di Blasio L, Gagliardi PA, Puliafito A,
Sessa R, Seano G, Bussolino F and Primo L: PDK1 regulates focal
adhesion disassembly by modulating endocytosis of αvβ3 integrin. J
Cell Sci. 128:863–877. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Raimondi C, Chikh A, Wheeler AP, Maffucci
T and Falasca M: Correction: A novel regulatory mechanism links
PLCγ1 to PDK1. J Cell Sci. 130:10162017. View Article : Google Scholar
|
|
12
|
Gagliardi PA, di Blasio L, Puliafito A,
Seano G, Sessa R, Chianale F, Leung T, Bussolino F and Primo L:
PDK1-mediated activation of MRCKα regulates directional cell
migration and lamellipodia retraction. J Cell Biol. 206:415–434.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lian S, Shao Y, Liu H, He J, Lu W, Zhang
Y, Jiang Y and Zhu J: PDK1 induces JunB, EMT, cell migration and
invasion in human gallbladder cancer. Oncotarget. 6:29076–29086.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zabkiewicz J, Pearn L, Hills RK, Morgan
RG, Tonks A, Burnett AK and Darley RL: The PDK1 master kinase is
over-expressed in acute myeloid leukemia and promotes PKC-mediated
survival of leukemic blasts. Haematologica. 99:858–864. 2014.
View Article : Google Scholar :
|
|
15
|
Qin L, Tian Y, Yu Z, Shi D, Wang J, Zhang
C, Peng R, Chen X, Liu C, Chen Y, et al: Targeting PDK1 with
dichloroacetophenone to inhibit acute myeloid leukemia (AML) cell
growth. Oncotarget. 7:1395–1407. 2016. View Article : Google Scholar :
|
|
16
|
Scortegagna M, Ruller C, Feng Y, Lazova R,
Kluger H, Li JL, De SK, Rickert R, Pellecchia M, Bosenberg M, et
al: Genetic inactivation or pharmacological inhibition of Pdk1
delays development and inhibits metastasis of Braf(V600E):Pten(−/−)
melanoma. Oncogene. 33:4330–4339. 2014. View Article : Google Scholar
|
|
17
|
Yang Z, Wu Z, Liu T, Han L, Wang C, Yang B
and Zheng F: Upregulation of PDK1 associates with poor prognosis in
esophageal squamous cell carcinoma with facilitating tumorigenicity
in vitro. Med Oncol. 31:3372014. View Article : Google Scholar
|
|
18
|
Choucair KA, Guérard KP, Ejdelman J,
Chevalier S, Yoshimoto M, Scarlata E, Fazli L, Sircar K, Squire JA,
Brimo F, et al: The 16p13.3 (PDPK1) Genomic Gain in Prostate
Cancer: A Potential Role in Disease Progression. Transl Oncol.
5:453–460. 2012. View Article : Google Scholar
|
|
19
|
Raimondi C, Calleja V, Ferro R, Fantin A,
Riley AM, Potter BV, Brennan CH, Maffucci T, Larijani B and Falasca
M: A Small molecule inhibitor of PDK1/PLCγ1 interaction blocks
breast and melanoma cancer cell invasion. Sci Rep. 6:261422016.
View Article : Google Scholar
|
|
20
|
Yu J, Chen KS, Li YN, Yang J and Zhao L:
Silencing of PDK1 gene expression by RNA interference suppresses
growth of esophageal cancer. Asian Pac J Cancer Prev. 13:4147–4151.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xie Z, Yuan H, Yin Y, Zeng X, Bai R and
Glazer RI: 3-phosphoinositide-dependent protein kinase-1 (PDK1)
promotes invasion and activation of matrix metalloproteinases. BMC
Cancer. 6:772006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maurer M, Su T, Saal LH, Koujak S, Hopkins
BD, Barkley CR, Wu J, Nandula S, Dutta B, Xie Y, et al:
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions
on the phosphatidylinositol 3-kinase pathway in breast carcinoma.
Cancer Res. 69:6299–6306. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zeng X, Xu H and Glazer RI: Transformation
of mammary epithelial cells by 3-phosphoinositide-dependent protein
kinase-1 (PDK1) is associated with the induction of protein kinase
Calpha. Cancer Res. 62:3538–3543. 2002.PubMed/NCBI
|
|
24
|
Du J, Yang M, Chen S, Li D, Chang Z and
Dong Z: PDK1 promotes tumor growth and metastasis in a spontaneous
breast cancer model. Oncogene. 35:3314–3323. 2016. View Article : Google Scholar
|
|
25
|
Wang Y, Fu L, Cui M, Wang Y, Xu Y, Li M
and Mi J: Amino acid transporter SLC38A3 promotes metastasis of
non-small cell lung cancer cells by activating PDK1. Cancer Lett.
393:8–15. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li W, Song R, Fang X, Wang L, Chen W, Tang
P, Yu B, Sun Y and Xu Q: SBF-1, a synthetic steroidal glycoside,
inhibits melanoma growth and metastasis through blocking
interaction between PDK1 and AKT3. Biochem Pharmacol. 84:172–181.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wen W, Liu G, Jin K and Hu X: TGF-β1
induces PGP9.5 expression in CAFs to promote the growth of
colorectal cancer cells. Oncol Rep. 37:115–122. 2017. View Article : Google Scholar
|
|
28
|
Eferl R and Wagner EF: AP-1: A
double-edged sword in tumorigenesis. Nat Rev Cancer. 3:859–868.
2003. View Article : Google Scholar
|
|
29
|
Gokulnath M, Swetha R, Thejaswini G,
Shilpa P and Selvamurugan N: Transforming growth factor-β1
regulation of ATF-3, c-Jun and JunB proteins for activation of
matrix metal-loproteinase-13 gene in human breast cancer cells. Int
J Biol Macromol. 94A:370–377. 2017. View Article : Google Scholar
|
|
30
|
Ohba S, Hirose Y, Kawase T and Sano H:
Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced
cytotoxicity in human glioma cells. J Neurooncol. 95:307–316. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tamburrino A, Molinolo AA, Salerno P,
Chernock RD, Raffeld M, Xi L, Gutkind JS, Moley JF, Wells SA Jr and
Santoro M: Activation of the mTOR pathway in primary medullary
thyroid carcinoma and lymph node metastases. Clin Cancer Res.
18:3532–3540. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Allen M, Bjerke M, Edlund H, Nelander S
and Westermark B: Origin of the U87MG glioma cell line: Good news
and bad news. Sci Transl Med. 8:pp. 354re32016, View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Luo D, Chen H, Lu P, Li X, Long M, Peng X,
Huang M, Huang K, Lin S, Tan L, et al: CHI3L1 overexpression is
associated with metastasis and is an indicator of poor prognosis in
papillary thyroid carcinoma. Cancer Biomark. 18:273–284. 2017.
View Article : Google Scholar
|
|
34
|
Luo D, Chen W, Tian Y, Li J, Xu X, Chen C
and Li F: Serpin peptidase inhibitor, clade A member 3 (SERPINA3),
is overexpressed in glioma and associated with poor prognosis in
glioma patients. OncoTargets Ther. 10:2173–2181. 2017. View Article : Google Scholar
|
|
35
|
Wang W, Wang L, Mizokami A, Shi J, Zou C,
Dai J, Keller ET, Lu Y and Zhang J: Down-regulation of E-cadherin
enhances prostate cancer chemoresistance via Notch signaling. Chin
J Cancer. 36:352017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
37
|
Zhang Y, Zhang LX, Liu XQ, Zhao FY, Ge C,
Chen TY, Yao M and Li JJ: Id4 promotes cell proliferation in
hepatocellular carcinoma. Chin J Cancer. 36:192017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Luo D, Chen H, Li X, Lu P, Long M, Peng X,
Lin S, Tan L, Zhu Y, Ouyang N, et al: Activation of the ROCK1/MMP-9
pathway is associated with the invasion and poor prognosis in
papillary thyroid carcinoma. Int J Oncol. 51:1209–1218. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu N, Zhang L, Wang Z, Cheng Y, Zhang P,
Wang X, Wen W, Yang H, Liu H, Jin W, et al: MicroRNA-101 inhibits
proliferation, migration and invasion of human glioblastoma by
targeting SOX9. Oncotarget. 8:19244–19254. 2017.
|
|
40
|
Chen H, Luo D, Zhang L, Lin X, Luo Q, Yi
H, Wang J, Yan X, Li B, Chen Y, et al: Restoration of p53 using the
novel MDM2-p53 antagonist APG115 suppresses dedifferentiated
papillary thyroid cancer cells. Oncotarget. 8:43008–43022.
2017.PubMed/NCBI
|
|
41
|
Killela PJ, Pirozzi CJ, Healy P, Reitman
ZJ, Lipp E, Rasheed BA, Yang R, Diplas BH, Wang Z, Greer PK, et al:
Mutations in IDH1, IDH2, and in the TERT promoter define clinically
distinct subgroups of adult malignant gliomas. Oncotarget.
5:1515–1525. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Laws ER, Parney IF, Huang W, Anderson F,
Morris AM, Asher A, Lillehei KO, Bernstein M, Brem H, Sloan A, et
al Glioma Outcomes Investigators: Survival following surgery and
prognostic factors for recently diagnosed malignant glioma: Data
from the Glioma Outcomes Project. J Neurosurg. 99:467–473. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Stetson LC, Dazard JE and Barnholtz-Sloan
JS: Protein Markers Predict Survival in Glioma Patients. Mol Cell
Proteomics. 15:2356–2365. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Woolf EC and Scheck AC: Metabolism and
glioma therapy. CNS Oncol. 1:7–10. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dupuy F, Tabariès S, Andrzejewski S, Dong
Z, Blagih J, Annis MG, Omeroglu A, Gao D, Leung S, Amir E, et al:
PDK1-dependent metabolic reprogramming dictates metastatic
potential in breast cancer. Cell Metab. 22:577–589. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lohneis P, Darb-Esfahani S, Dietel M,
Braicu I, Sehouli J and Arsenic R: PDK1 is expressed in ovarian
serous carcinoma and correlates with improved survival in
high-grade tumors. Anticancer Res. 35:6329–6334. 2015.PubMed/NCBI
|
|
47
|
Wu YH, Chang TH, Huang YF, Chen CC and
Chou CY: COL11A1 confers chemoresistance on ovarian cancer cells
through the activation of Akt/c/EBPβ pathway and PDK1
stabilization. Oncotarget. 6:23748–23763. 2015.PubMed/NCBI
|
|
48
|
Tan J, Lee PL, Li Z, Jiang X, Lim YC, Hooi
SC and Yu Q: B55β-associated PP2A complex controls PDK1-directed
myc signaling and modulates rapamycin sensitivity in colorectal
cancer. Cancer Cell. 18:459–471. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang Q, Yan HB, Wang J, Cui SJ, Wang XQ,
Jiang YH, Feng L, Yang PY and Liu F: Chromatin remodeling gene
AT-rich interactive domain-containing protein 1A suppresses gastric
cancer cell proliferation by targeting PIK3CA and PDK1. Oncotarget.
7:46127–46141. 2016.PubMed/NCBI
|
|
50
|
Ferro R and Falasca M: Emerging role of
the KRAS-PDK1 axis in pancreatic cancer. World J Gastroenterol.
20:10752–10757. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kobes JE, Daryaei I, Howison CM, Bontrager
JG, Sirianni RW, Meuillet EJ and Pagel MD: Improved treatment of
pancreatic cancer with drug delivery nanoparticles loaded with a
novel AKT/PDK1 inhibitor. Pancreas. 45:1158–1166. 2016. View Article : Google Scholar :
|
|
52
|
Hu Y, Sun H, Owens RT, Gu Z, Wu J, Chen
YQ, O’Flaherty JT and Edwards IJ: Syndecan-1-dependent suppression
of PDK1/ Akt/bad signaling by docosahexaenoic acid induces
apoptosis in prostate cancer. Neoplasia. 12:826–836. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Castel P, Ellis H, Bago R, Toska E, Razavi
P, Carmona FJ, Kannan S, Verma CS, Dickler M, Chandarlapaty S, et
al: PDK1-SGK1 signaling sustains AKT-independent mTORC1 activation
and confers resistance to PI3Kα inhibition. Cancer Cell.
30:229–242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lin HJ, Hsieh FC, Song H and Lin J:
Elevated phosphorylation and activation of PDK-1/AKT pathway in
human breast cancer. Br J Cancer. 93:1372–1381. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Tan J, Li Z, Lee PL, Guan P, Aau MY, Lee
ST, Feng M, Lim CZ, Lee EY, Wee ZN, et al: PDK1 signaling toward
PLK1-MYC activation confers oncogenic transformation,
tumor-initiating cell activation, and resistance to mTOR-targeted
therapy. Cancer Discov. 3:1156–1171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Han L, Zhang G, Zhang N, Li H, Liu Y, Fu A
and Zheng Y: Prognostic potential of microRNA-138 and its target
mRNA PDK1 in sera for patients with non-small cell lung cancer. Med
Oncol. 31:1292014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Meng Q and Xia Y: c-Jun, at the crossroad
of the signaling network. Protein Cell. 2:889–898. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Shaulian E and Karin M: AP-1 as a
regulator of cell life and death. Nat Cell Biol. 4:E131–E136. 2002.
View Article : Google Scholar : PubMed/NCBI
|
